# Topical Roflumilast in Adults With Atopic Dermatitis

> **NCT01856764** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** 0.5% Roflumilast Cream
- **DRUG:** Vehicle Cream

## Key facts

- **NCT ID:** NCT01856764
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856764, "Topical Roflumilast in Adults With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01856764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*